Last Updated on October 10, 2024 by The Health Master
Alembic Pharmaceuticals Ltd on Tuesday said its joint venture, Aleor Dermaceuticals Ltd (Aleor), has received final approval from the US health regulator for its generic version of Nystatin and Triamcinolone Acetonide ointment used for the treatment of cutaneous candidiasis.
Cutaneous candidiasis is an infection of the skin and nails caused by the candida fungus.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment of strength 100,000 units/gram, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Nystatin and Triamcinolone Acetonide ointment of Taro Pharmaceuticals USA Inc, it added.
The company further said Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis. It has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.
Citing IQVIA data, Alembic said Nystatin and Triamcinolone Acetonide ointment has an estimated market size of USD 4 million for the 12-month period ending December 2021.
USFDA gives nod to Aleor for Nystatin and Triamcinolone Acetonide Ointment
USFDA approves expanded use of cancer drug Opdivo
USFDA gives nod to Lupin for generic Jublia topical solution
USFDA gives nod to Lupin for Sevelamer Hydrochloride Tablets, 800 mg
USFDA approves this drug for bone marrow cancer treatment
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
Govt amends rules to allow import license for Medical Devices: Read
IPC flags safety alert against Blood Pressure drug, Losartan
USFDA gives nod to Aleor for Nystatin and Triamcinolone Acetonide Ointment
ICMR in collaboration with pharma companies to develop Dengue vaccine
DCGI gives nod to Zydus Oxemia to treat anaemia
Pfizer recalls this BP drug on potential cancer-causing impurity
Phase-3 Clinical Trial permission of Covovax as booster dose recommended
NPPA fixes retail price of Normal Human Immunoglobulin 5% Solution
Clarification sought from CDSCO on approval status of Clotrimazole 1% mouth paint
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
